ARTICLE | Regulation
Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more
August 13, 2020 1:45 AM UTC
FDA approves a second targeted DMD therapy
NS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. Vyondys golodirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT) was the first targeted drug approved for the indication. NS Pharma is a Nippon Shinyaku Co. Ltd. (Tokyo:4516) subsidiary.
Trevena’s opioid agonist approved...